Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

To address proportionality in the classes of directors based on the classification of the Board of Directors (the "Board") of Sucampo Pharmaceuticals, Inc. (the "Company"), on December 14, 2012, William Ashton resigned as a Class II director of the Board and was immediately re-elected to the Board by unanimous vote of the Board as a Class III director. Mr. Ashton was a member and the Chair of the Compensation Committee, a member of the Audit Committee, a member of the Nominating and Corporate Governance Committee and a member and Chair of the Commercialization Committee. Mr. Ashton was also reappointed to chair and be a member of the same committees as he was prior to his resignation. Mr. Ashton will not receive any new or additional compensation as a result of his reappointment but will continue to be entitled to receive the same compensation he had received prior to his resignation. The election of Class I directors will be voted on by stockholders at the annual meeting in 2013; the election of Class II directors will be voted on by stockholders at the annual meeting in 2014; and the election of Class III directors will be voted on by stockholders at the annual meeting in 2015. The classification of the Board currently is as follows: Timothy Maudlin and Daniel Getman, Class I; Ryuji Ueno and Gayle Dolecek, Class II; and William Ashton and Anthony Celeste, Class III.

---